Fox Chase Cancer Center News

Study by Fox Chase Researchers Indicates Gene Mutations From UV Exposure May Play Role in Melanoma Malignancy

PHILADELPHIA (June 29, 2020)—Researchers at Fox Chase Cancer Center recently conducted a study analyzing the impact of sun exposure and tanning patterns on gene mutations in patients with advanced melanoma. Those who experienced blistering sunburn had a higher number of gene mutations in their tumors compared to those who did not experience blistering sunburn.

VIEW STORY

Fox Chase Cancer Center Welcomes Weier Li

PHILADELPHIA (June 24, 2020) – Fox Chase Cancer Center announces the hiring of Weier Li, MD, who will join the Department of Diagnostic Imaging as a full time body imager. Li will join Fox Chase as an assistant professor.

VIEW STORY

Fox Chase Researchers Receive Grant to Study Approaches for Empowering Asian American Women in Cervical Cancer Screening

PHILADELPHIA (June 22, 2020)—Carolyn Y. Fang, PhD, was recently awarded a grant for the first large-scale study evaluating a method that allows Asian American women to collect their own samples, which can then be tested for the presence of the human papilloma virus (HPV). Fang will be conducting the research with Grace X. Ma, PhD, multiple principal investigator for the study.

VIEW STORY

Fox Chase Researchers Identify Possible Biomarkers in Bladder Cancer Patients Receiving Therapy Before Surgery

PHILADELPHIA (June 18, 2020)—In a recent study, researchers at Fox Chase Cancer Center found that muscle-invasive bladder cancer patients with specific gene mutations have better survival outcomes when treated with chemotherapy before surgery. The five-year survival rate for patients with at least one mutation was 85 percent, compared to 45 percent for patients without a mutation.

VIEW STORY

Fox Chase-Temple University Hospital Bone Marrow Transplant Program Awarded FACT Reaccreditation

PHILADELPHIA (June 17, 2020) – The Fox Chase-Temple University Hospital Bone Marrow Transplant Program has been reaccredited for adult allogeneic and autologous hematopoietic progenitor cell transplantation, peripheral blood cellular therapy product collection, and cellular therapy product processing with minimal manipulation. Also included is a new accreditation for immune effector cells.

VIEW STORY